All In MedTech

FDA Clearance Tracker · P180050-S009

Barostim System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Dec 22, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P180050-S009
Device name
Barostim System
Applicant
Cvrx, Inc.
Applicant location
Minneapolis, MN
Received
Jun 7, 2023
Decided
Dec 22, 2023
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P180050

Device type

Device class
Class III
Regulation
21 CFR 870.3850

Every decision under product code DSR

FDA's approval statement

As written in FDA's record.

Approval for updates to the indications for use statement and inclusion of the post approval study (BeAT-HF) data into the labeling.

Source documents

Other decisions for Cvrx, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.